top of page
Tânia S. Morais
Use tab to navigate through the menu items.
Are smart delivery systems the solution to overcome the lack of selectivity of current metallodrugs in cancer therapy?
Emerging molecular receptors for the specific-target delivery of ruthenium and gold complexes into cancer cells
Novel “ruthenium cyclopentadienyl”–peptide conjugate complexes against human FGFR(+) breast cancer
Selected as HOT TOPIC
New copper(i) complexes selective for prostate cancer cells
In Vivo Performance of a Ruthenium-cyclopentadienyl Compound in an Orthotopic Triple Negative Breast Cancer Model
Tracking antitumor metallodrugs: promising agents with the Ru(II)- and Fe(II)-cyclopentadienyl scaffolds
New water-soluble ruthenium(II) cytotoxic complex: Biological activity and cellular distribution
bottom of page